Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
Hepion Pharmaceuticals (OTCQB:HEPA), a clinical stage biopharmaceutical company, has announced its successful transition to the OTCQB Venture Market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Hepion Pharmaceuticals (OTCQB:HEPA), a clinical stage biopharmaceutical company, has announced its successful transition to the OTCQB Venture Market. The company's common stock commenced trading on the OTCQB on June 25, 2025, under the symbol HEPA.
Hepion focuses on developing and commercializing diagnostic tests for multiple conditions including celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori, and hepatocellular carcinoma (HCC).
Positive
- None.
Negative
- Downgrade from previous listing to OTCQB market indicates potential delisting concerns
- Trading on OTCQB typically means reduced liquidity and institutional investor access compared to major exchanges
Details
News Market Reaction – HEPA
The recorded move for HEPA in the trading session of this news was -1.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company’s common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA.
About Hepion Pharmaceuticals
Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma.
For further information, please contact:
Hepion Pharmaceuticals
info@hepionpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.